Tsu Tshen CHUANG,Ann Jacqueline HUNTER,David John VIRLEY
申请号：
US16218186
公开号：
US20190350927A1
申请日:
2018.12.12
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, and its use for the treatment of a) psychiatric disorders with prominent cognitive deficits e.g. chronic PTSD (Post traumatic stress disorder)； b) non-degenerative disorders with prominent cognitive deficits e.g. MS (multiple Sclerosis), post-chemotherapy, post-CABG (Coronary artery bypass graft), post-stroke； and/or c) paediatric disorders e.g. autism, mental retardation and learning disabilities, in particular for the treatment of schizophrenia.
